Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
The present disclosure provides polypeptide conjugates comprising GLP-1 receptor agonist and a peptide linker, and liquid pharmaceutical compositions comprising the same. Methods of using such for treating diseases are also provided.
1. A liquid pharmaceutical composition, comprising a polypeptide conjugate and a pharmaceutically acceptable excipient, wherein:
the polypeptide conjugate comprises a polypeptide portion and a conjugate portion,
the polypeptide portion comprises a single biologically active peptide and a peptide linker, wherein the biologically active peptide is attached to N-terminus of the peptide linker and comprises GLP-1; and
the conjugate portion comprises a first clearance-reducing moiety (CRM) conjugated to a first CRM residue in the peptide linker, and a second CRM conjugated to a second CRM residue in the polypeptide portion,
wherein the first CRM residue and the second CRM residue are both lysine residues, and the polypeptide conjugate comprises only two lysine residues,
wherein:
the polypeptide portion comprises an amino acid sequence of SEQ ID NO: 51, and is conjugated with the first CRM and the second CRM respectively at 26K and 76K;
the polypeptide portion comprises an amino acid sequence of SEQ ID NO: 53, and is conjugated with the first CRM and the second CRM respectively at 26K and 84K;
the polypeptide portion comprises an amino acid sequence of SEQ ID NO: 54, and is conjugated with the first CRM and the second CRM respectively at 26K and 68K;
the polypeptide portion comprises an amino acid sequence of SEQ ID NO: 57, and is conjugated with the first CRM and the second CRM respectively at 26K and 76K;
the polypeptide portion comprises an amino acid sequence of SEQ ID NO: 58, and is conjugated with the first CRM and the second CRM respectively at 26K and 84K;
the polypeptide portion comprises an amino acid sequence of SEQ ID NO: 59, and is conjugated with the first CRM and the second CRM respectively at 26K and 68K;
the polypeptide portion comprises an amino acid sequence of SEQ ID NO: 85, and is conjugated with the first CRM and the second CRM respectively at 26K and 96K;
the polypeptide portion comprises an amino acid sequence of SEQ ID NO: 86, and is conjugated with the first CRM and the second CRM respectively at 26K and 60K;
wherein the first clearance-reducing moiety (CRM) and the second CRM both have the structure of below formula:
wherein the pharmaceutical composition has about 20-120 mg/ml of the polypeptide conjugate; and
wherein the pharmaceutical composition has a pH of about 6.5 to about 7.8.
2. The pharmaceutical composition of claim 1 , wherein the polypeptide conjugate has the structure shown below:
3. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable excipient comprises a buffer and an isotonic agent.
4. The pharmaceutical composition of claim 3 , wherein the buffer is a phosphate buffer.
5. The pharmaceutical composition of claim 4 , wherein the phosphate buffer is disodiumhydrogen phosphate dodecahydrate, wherein the disodiumhydrogen phosphate dodecahydrate is present in a concentration of about 0.01-15 mg/mL.
6. The pharmaceutical composition of claim 4 , wherein the phosphate buffer is disodium phosphate dihydrate.
7. The pharmaceutical composition of claim 3 , wherein the buffer is a citrate buffer.
8. The pharmaceutical composition of claim 3 , wherein the buffer is a histidine buffer.
9. The pharmaceutical composition of claim 3 , wherein the isotonic agent is sodium chloride, or wherein the isotonic agent is propylene glycol.
10. The pharmaceutical composition of claim 3 , wherein the isotonic agent is mannitol.
11. The pharmaceutical composition of claim 3 , wherein the pharmaceutical excipient further comprises a preservative, a chelating agent, and/or a stabilizer.
12. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition has a pH of about 6.5 to 7.4.
13. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition has about 20-80 mg/ml, or 20-100 mg/ml of the polypeptide conjugate.
14. The pharmaceutical composition of claim 3 , comprising:
about 20-120 mg/ml of the polypeptide conjugate;
a buffer selected from the group consisting of phosphate buffer, citrate buffer, acetate buffer, histidine buffer, glycine buffer, carbonate buffer, borate buffer, glutamate buffer, glycylglycine buffer, lysine buffer, and arginine buffer;
an isotonic agent selected from the group consisting of sodium chloride, glycerol, sorbitol, sucrose, propylene glycol, mannitol, glycine, lactose monohydrate, arginine, myoinositol and dimethylsulfon; and
a pH of about 6.5 to about 7.8.
15. The pharmaceutical composition of claim 3 , comprising:
about 20-80 mg/mL, 20-100 mg/ml or 20-120 mg/mL of the polypeptide conjugate, wherein the polypeptide portion of the polypeptide conjugate comprises an amino acid sequence of SEQ ID NO: 57, and is conjugated with the first CRM and the second CRM respectively at 26K and 76K;
about 0.5-5 mg/mL phosphate buffer, about 1-50 mM citrate buffer, or about 0.5-10 mg/mL histidine buffer;
an isotonic agent selected from the group consisting of 5-15 mg/ml sodium chloride, 1-50 mg/mL propylene glycol, and 30-50 mg/mL mannitol; and
a pH of about 6.5 to about 7.8.
16. The pharmaceutical composition of claim 1 , comprising:
about 20-80 mg/mL, 20-100 mg/ml or 20-120 mg/mL of the polypeptide conjugate,
wherein the polypeptide portion of the polypeptide conjugate comprises an amino acid sequence of SEQ ID NO: 57, and is conjugated with the first CRM and the second CRM respectively at 26K and 76K;
about 0.5-5 mg/mL phosphate buffer;
5-15 mg/ml sodium chloride; and
a pH of about 6.5 to about 7.8.